

Proceedings

Open Access

Adjusting for HLA-DR β 1 in a genome-wide association analysis of rheumatoid arthritis and related biomarkers

Abigail G Matthews*¹, Jia Li², Chunsheng He¹, Jurg Ott^{1,3}
and Mariza de Andrade²

Addresses: ¹Laboratory of Statistical Genetics, Rockefeller University, Box 192, 1230 York Avenue, New York, NY 10065, USA, ²Department of Health Sciences Research, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA and ³Beijing Institute of Genomics, Chinese Academy of Sciences, Number 7 Bei Tu Cheng West Road, Chaoyang District, Beijing 100029, PR China

E-mail: Abigail G Matthews* - amatthews@rockefeller.edu; Jia Li - jjaiyasc@gmail.com; Chunsheng He - che@rockefeller.edu; Jurg Ott - ott@rockefeller.edu; Mariza de Andrade - mandrade@mayo.edu

*Corresponding author

from Genetic Analysis Workshop 16
St Louis, MO, USA 17-20 September 2009

Published: 15 December 2009

BMC Proceedings 2009, 3(Suppl 7):S12 doi: 10.1186/1753-6561-3-S7-S12

This article is available from: <http://www.biomedcentral.com/1753-6561/3/S7/S12>

© 2009 Matthews et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: There is a long-established association between rheumatoid arthritis and HLA-DR β 1. The shared epitope (SE) allele is an indicator of the presence of any of the HLA-DR β 1 alleles associated with RA. Other autoantibodies are also associated with RA, specifically rheumatoid factor IgM (RFUW) and anti-cyclic citrullinated peptide (anti-CCP).

Methods: Using the Genetic Analysis Workshop 16 North American Rheumatoid Arthritis Consortium genome-wide association data, we sought to find non-HLA-DR β 1 genetic associations by stratifying across SE status, and using the continuous biomarker phenotypes of RFUW and anti-CCP. To evaluate the binary RA phenotype, we applied the recently developed FP test and compared it to logistic regression or a genotype count-based test. We adjusted for multiple testing using the Bonferroni correction, the Q value approach, or permutation-based *p*-values. A case-only analysis of the biomarkers RFUW and anti-CCP used linear regression and ANOVAs.

Results: The initial genome-wide association analysis using all cases and controls provides substantial evidence of an association on chromosomes 9 and 2 within the immune system-related gene *UBXD2*. In SE-positive subjects, many single-nucleotide polymorphisms were significant, including some on chromosome 6. Due to very few SE negative cases, we had limited power to detect associations in SE negative subjects. We were also unable to find genetic associations with either RFUW or anti-CCP.

Conclusion: Our analyses have confirmed previous findings for genes *PTPN22* and *C5*. We also identified a novel candidate gene on chromosome 2, *UBXD2*. Results suggest FP test may be more powerful than the genotype count-based test.

Background

Genetic associations between rheumatoid arthritis (RA) and HLA loci have been known for some 30 years [1] but only in recent times, with the availability of dense genetic maps, have associations with other genomic areas been discovered. An affected-sibpair analysis demonstrated significant linkage of RA with single-nucleotide polymorphisms (SNPs) at chromosomes 2q33 and 11p12 with additional, non-significant, linkage to SNPs on chromosomes 4, 7, 12, 16, and 18 [2]. Genome-wide association studies have confirmed and refined associations with HLA variants [3-5], specifically with HLA-DR β 1. The high risk alleles for HLA-DR β 1, commonly referred to as the shared epitope (SE), were found to be highly associated with RA [6,7]. Thus, individuals can be characterized as SE positive (at least one high risk allele) or SE negative (no high risk alleles). Lee et al. [8] have recently shown that there are associations within the major histocompatibility complex (MHC) that are independent of HLA-DR β 1. Autoantibodies, such as rheumatoid factor IgM (RFUW) and anti-cyclic citrullinated peptide (anti-CCP) have been shown to co-occur with RA [9-11]. Thus, genetic predictors of these two biomarkers may also be of interest.

Using unrelated cases and controls from the North American Rheumatoid Arthritis Consortium (NARAC) [12] provided by the Genetic Analysis Workshops 16 and previously analyzed by Plenge et al. [4], we sought to find non-HLA-DR β 1 genetic associations separately in SE positive and SE negative individuals. The literature does not contain any analysis of genome-wide association adjusted for SE status; thus, our primary objective was to stratify the genetic analyses by SE status. Our aims are to identify genomic regions in SE negative individuals that may act independently of the SE in RA development, to evaluate any potential effect modification or epistasis with HLA-DR β 1 in SE positive individuals, and to identify new genomic regions associated with the continuous phenotypes of RFUW and anti-CCP. We also sought to implement the recently proposed FP test [13] and compare it to other methods of analysis.

Methods

Quality control

As previously noted, heterogeneity in this dataset is largely due to SNPs with incomplete genotyping [4]. Thus, we focused on the subset of SNPs with call rates exceeding 95.5%. Markers with only one genotype observed were excluded as well as those with a minor allele frequency (MAF) less than 5%. Further, SNPs with the χ^2 for Hardy-Weinberg disequilibrium greater than 50 were also removed from consideration. Individuals with more than 20% of SNPs missing were excluded. Only autosomal SNPs were analyzed in this study.

Statistical analysis

As an initial pass through the data, a genome-wide association analysis was performed using the FP test and a genotype-based χ^2 test of association for all non-chromosome 6 SNPs. These SNPs were ignored at first because of the potential for disequilibrium with the HLA-DR β 1. These analyses considered all cases and controls, that is, the number of SE alleles was not accounted for in any way. The FP test evaluates differences in allele frequencies and inbreeding coefficients between cases and controls. Both statistics were implemented using the *sumstat* program [14] which computes permutation-based *p*-values such that further adjustment for multiple testing is unnecessary. For all analyses, 5000 permutations were used.

For the genome-wide association analyses of RA adjusting for SE status, we performed multiple methods of analyses separately in those who are SE positive and those who are SE negative. Three different analytic methods were applied to each SNP. First, logistic regressions were implemented in PLINK [15] with sex as an additional covariate. For these results, multiple comparisons were adjusted for using the Bonferroni correction as well as the Q value approach [16], which controls the false discovery rate (FDR). Due to the large number of statistically significant SNPs in this analysis, all subsequent analyses do not consider any SNPs on chromosome 6. As in the initial analyses, both the χ^2 test of genotype-based association and the FP test were implemented in *sumstat* using 5000 permutations.

Genetic analysis of the two biomarkers RFUW and anti-CCP were conducted in a similar fashion, but only considering the 868 cases. Since these outcome variables are continuous, linear regression with sex as an additional covariate was implemented using PLINK. The quantile rank transformation was applied to both outcomes to satisfy distribution assumptions. Multiple testing was adjusted for using the Bonferroni and Q value approaches. ANOVAs were used to analyze the biomarkers separately and jointly using *sumstat* and its permutation-based *p*-values. Due to the normality assumptions of this approach, anti-CCP and RFUW levels were transformed using the normal quantile transformation. For each SNP, three tests were considered: i) ANOVA considering only anti-CCP, ii) ANOVA considering RFUW alone, and iii) the maximum ANOVA statistic for anti-CCP and RFUW. The permutations implemented by *sumstat* allow for control of the type I error rate for the maximum statistic and multiple testing simultaneously.

Results

Quality control

Initially, 531,689 autosomal SNPs were available for analysis. Due to only one genotype being observed,

1,771 SNPs were removed. With regards to substantial deviations from Hardy-Weinberg equilibrium, 22 SNPs were also removed. Further, another 38,829 SNPs did not pass quality control because their MAF was less than 5%. After also removing SNPs with call rates less than 95.5%, we were able to consider 481,486 autosomal SNPs. For the genotype-based analyses and FP tests, chromosome 6 SNPs were excluded, leaving 338,671 for this set of analyses. Because the lowest call rate was over 97%, we considered all 2062 subjects.

Initial genome-wide association analysis

Twelve non-chromosome 6 SNPs were statistically significant in the initial pass through the data using the FP or χ^2 test of association with genotype counts. Table 1 describes these "best" non-chromosome 6 SNPs and the permutation-based p -values for both tests. There are six SNPs on chromosome 9 that are statistically significant at the 0.05 level, all within 65 kb of each other. The remaining significant SNPs are located on chromosomes 1, 2, 8, and 10.

Adjusting for SE status

Of the 868 cases, 810 were SE positive; and of the 1194 controls, only 541 were SE positive. Figure 1A gives the results of the logistic regression analyses of all autosomal SNPs in the 1351 individuals who are SE positive. Using the Bonferroni correction, there were statistically significant SNPs on virtually every autosome. The most highly significant SNPs are located on chromosome 6 in the HLA region, with several p -values less than 10^{-25} . Figure 1B plots the results of the logistic regression analyses of all autosomal SNPs in the SE negative participants. None of the over 480,000 SNPs were statistically significant in the SE negative individuals after adjustment for multiple comparisons with the Bonferroni or Q value corrections. When the chromosome 6 SNPs are excluded from analysis and the FP test is implemented, only one SNP was statistically significant for SE positive subjects: rs2900180

($p = 0.0196$) on chromosome 9. In SE negative individuals, no SNPs were statistically significant (all $p > 0.35$) using the FP test.

Analysis of anti-CCP and rheumatoid factor IgM

The quantitative trait analyses of anti-CCP and RFUW were performed using cases only because this information was only available on the 868 subjects with RA. Not a single SNP was significant using any of the methods above. Due to the small sample size and the fact that all subjects had RA, we may have lacked power to detect any genetic association with levels of anti-CCP or RFUW.

Discussion


When considering all cases and controls regardless of SE status, 12 SNPs were statistically significant and spread across chromosomes 1, 2, 8, 9, and 10. The most significant SNP, rs2476601, is located on chromosome 1 less than 1 Mb from the PTPN22 gene, which has been shown to be associated with RA [14,17]. Six SNPs on chromosome 9 were also significant with the FP test, and they are all located in the same region: 120.72 to 120.79 Mb. These results may be due to high linkage disequilibrium (LD); in fact, three pairs of these SNPs have r^2 greater than 0.8. This region of chromosome 9, located near the immunity-related complement compound 5 (C5) gene, has been previously identified as associated with RA [4,18]. Three new associations are suggested by our analyses. On chromosome 8, three SNPs were statistically significant and are all located within 10 kb of each other. Yet another SNP was significant on chromosome 10 using the FP test, but was not significant using the genotype-based χ^2 test. Interestingly, we found evidence of an association on chromosome 2 at rs1446585, which is 35 Mb from a signal reported by Plenge et al. [4]. Our SNP is located within the *UBXD2* gene, which has been shown to be differentially expressed in the spleen and plays a role in the immune

Table 1: Analysis of non-chromosome 6 SNPs using all subjects

SNP ID	Chromosome	Location (bp)	FP (p -value)	Genotype-based χ^2 (p -value)
rs2476601	1	114089610	<0.0001	<0.0001
rs2900180 ^a	9	120785936	0.003	0.014
rs3761847	9	120769793	0.006	0.031
rs881375	9	120732452	0.011	0.046
rs2671692	10	49767825	0.011	0.057
rs1953126	9	120720054	0.012	0.053
rs10760130	9	120781544	0.013	0.064
rs4921720	8	20397678	0.024	0.123
rs11204117	8	20396191	0.026	0.131
rs10106243	8	20388180	0.031	0.153
rs1446585	2	136241211	0.034	0.163
rs10985073	9	120723409	0.035	0.165

^aAlso significant using FP test only on individuals with shared epitopes.

A.



B.




Figure 1
Manhattan plots from the logistic regression analysis of RA stratifying by SE status. A, Results from the regression analyses in SE positive subjects adjusted for sex using all autosomal SNPs, including chromosome 6. B, Results from the regression analyses in SE negative subjects adjusted for sex using all autosomal SNPs, including chromosome 6.

system [19]. This is particularly of interest because RA is an autoimmune disease.

One goal of our genome-wide association analysis was to stratify by SE status, which has not been done previously for a genome-wide association study. Using the FP test on SE positive subjects, only one SNP was statistically significant, namely, rs2900180, which is located within approximately 2 Mb of *C5*. More SNPs were significant in this region near *C5* when all subjects were considered, but this difference does not imply epistasis between *C5* and HLA-DR β 1. It may only be due to the decrease in sample size. When restricting our analysis to SE negative individuals, none of the three tests yielded evidence of another gene associated with the development of RA. The increase in risk associated with the shared epitope allele is so great that very few of the cases were SE negative. With only 58 cases available for these analyses, it is not surprising no SNPs were significant. Although one of our main objectives was to identify genomic regions that may act independently on development and progression of RA, we were unable to do so with adequate power.

Our analyses of the biomarkers anti-CCP and RFUW yielded no significant results. Information on these continuous phenotypes was only available for the 868 cases, so the controls were not considered at all. Since all subjects had RA, it may be that there is no genetic association with either biomarker once disease has developed or progressed. RFUW is a measure of disease activity, so the lack of observed association may be due to the study design such that cases are fairly homogeneous in terms of disease severity.

Our final goal was to compare the implementation of the FP test with the other methods employed here. The significance level approach based on the FP test found far fewer SNPs to be statistically significant than the FDR approach (i.e., Q value) based on logistic regression analysis. This may show superiority of the concept of controlling the FDR over the significance level approach, and/or this difference may be due to inclusion in the logistic regression analysis of predictor variables, which were not considered in the FP analyses. Because permutation-based *p*-values were used for the FP and genotype-based χ^2 test in Table 1, the fact that the FP has smaller *p*-values than the χ^2 test for each SNP indicates the former may be more powerful.

Conclusion

This study demonstrates that there may be several genes that co-function with HLA-DR β 1 in the development and severity of RA, most likely on chromosome 9, such as *C5*, and other genes within the MHC region on chromosome 6. We have also identified another region

on chromosome 2 near the *UBXD2* gene as a candidate for follow-up study. In addition, we have shown that in order to identify new genomic regions that cause RA in SE negative individuals, an alternative study design must be implemented.

List of abbreviations used

Anti-CCP: Anti-cyclic citrullinated peptide; FDR: False discovery rate; LD: Linkage disequilibrium; MAF: Minor allele frequency; MHC: Major histocompatibility complex; NARAC: North American Rheumatoid Arthritis Consortium; RA: Rheumatoid arthritis; RFUW: Rheumatoid factor IgM; SE: Shared epitope; SNP: Single-nucleotide polymorphism.

Competing interests

There are no competing interests for AGM, JL, CH, JO or MdA.

Authors' contributions

For the first set of analyses using all SNPs, MdA specified the methodology and JL implemented the procedures. JO implemented the other analyses designed by himself, AGM and CH. This manuscript was principally written by AGM.

Acknowledgements

The Genetic Analysis Workshops are supported by NIH grant R01 GM031575 from the National Institute of General Medical Sciences. Partial funding for this study was provided by NIH grant HL87660 (MdA and JL), China NSFC grant 30730057 (JO), and NIMH grant MH44292 (JO, AGM, and CH). We also thank Martha E. Matsumoto for her help in performing additional analyses and aiding in the preparation of this manuscript.

This article has been published as part of *BMC Proceedings* Volume 3 Supplement 7, 2009: Genetic Analysis Workshop 16. The full contents of the supplement are available online at <http://www.biomedcentral.com/1753-6561/3?issue=S7>.

References

1. Thomsen M, Morling N, Snorrason E, Sveigaard A and Sørensen SF: **HLA-Dw4 and rheumatoid arthritis.** *Tissue Antigens* 1979, **13**:56–60.
2. Amos CI, Chen WV, Lee A, Li W, Kern M, Lundsten R, Batliwalla F, Wener M, Remmers E, Kastner DA, Criswell LA, Seldin MF and Gregersen PK: **High-density SNP analysis of 642 Caucasian families with rheumatoid arthritis identifies two new linkage regions on 11p12 and 2q33.** *Genes Immun* 2006, **7**:277–286.
3. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, Pe'er I, Burtt NP, Blumenstiel B, DeFelice M, Parkin M, Barry R, Winslow W, Healy C, Graham RR, Neale BM, Izmailova E, Roubenoff R, Parker AN, Glass R, Karlson EW, Maher N, Hafler DA, Lee DM, Seldin MF, Remmers EF, Lee AT, Padyukov L, Alfredsson L, Coby J, Weinblatt ME, Gabriel SB, Purcell S, Klareskog L, Gregersen PK, Shadick NA, Daly MJ and Altshuler D: **Two independent alleles at 6q23 associated with risk of rheumatoid arthritis.** *Nat Genet* 2007, **39**:1477–1482.
4. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, Liew A, Khalili H, Chandrasekaran A, Davies LR, Li W, Tan AK, Bonnard C, Ong RT, Thalamuthu A, Pettersson S, Liu C, Tian C, Chen WV, Carulli JP, Beckman EM, Altshuler D, Alfredsson L, Criswell LA, Amos CI, Seldin MF, Kastner DL, Klareskog L and Gregersen PK: **TRAF1-C5 as a risk locus for rheumatoid**

- arthritis - a genomewide study. *N Engl J Med* 2007, **357**:1199–1209.
5. Shibue T, Tsuchiya N, Komata T, Matsushita M, Shiota M, Ohashi J, Wakui M, Matsuta K and Tokunaga K: **Tumor necrosis factor alpha 5'-flanking region, tumor necrosis factor receptor II and HLA-DRB1 polymorphisms in Japanese patients with rheumatoid arthritis.** *Arthritis Rheum* 2000, **43**:753–757.
 6. Gregersen PK, Silver J and Winchester RJ: **The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis.** *Arthritis Rheum* 1987, **30**:1205–1213.
 7. Hughes LB, Morrison D, Kelley JM, Padilla MA, Vaughan LK, Westfall AO, Dwivedi H, Mikuls TR, Holers VM, Parrish LA, Alarcón GS, Conn DL, Jonas BL, Callahan LF, Smith EA, Gilkeson GS, Howard G, Moreland LW, Patterson N, Reich D and Bridges SL Jr: **The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture.** *Arthritis Rheum* 2008, **58**:349–358.
 8. Lee HS, Lee AT, Criswell LA, Seldin MF, Amos CI, Carulli JP, Navarrete C, Remmers EF, Kastner DL, Plenge RM, Li W and Gregersen PK: **Several regions in the major histocompatibility complex confer risk for anti-CCP-antibody positive rheumatoid arthritis, independent of the DRB1 locus.** *Mol Med* 2008, **14**:293–300.
 9. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, Hoogen van den FH, van 't Hof M, Putte van de LB, van Rijswijk MH, van Venrooij WJ and van Riel PL: **The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis.** *Arthritis Rheum* 2000, **43**:1831–1835.
 10. Lawrence JS: **Genetics of rheumatoid factor and rheumatoid arthritis.** *Clin Exp Immunol* 1967, **2**:769–783.
 11. Nienhuis RLF and Mandema E: **A new serum factor in patients with rheumatoid arthritis: The antiperinuclear factor.** *Ann Rheum Dis* 1964, **23**:302–305.
 12. **North American Rheumatoid Arthritis Consortium.** <http://www.naracstudy.org/>.
 13. Zhang Q, Wang S and Ott J: **Combining identity by descent and association in genetic case-control studies.** *BMC Genet* 2008, **9**:42.
 14. **sumstat.** <http://www.genemapping.cn/sumstat.html>.
 15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ and Sham PC: **PLINK: a tool set for whole-genome association and population-based linkage analyses.** *Am J Hum Genet* 2007, **81**:559–575.
 16. Storey JD and Tibshirani R: **Statistical significance for genome-wide studies.** *Proc Natl Acad Sci USA* 2003, **100**:9440–9445.
 17. Begovich AB, Carlton VE, Honigberg LA, Schrod SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoecker JM, Conn MT, Chang M, Chang SY, Saiki RK, Catanese JJ, Leong DU, Garcia VE, McAllister LB, Jeffery DA, Lee AT, Batliwalla F, Remmers E, Criswell LA, Seldin MF, Kastner DL, Amos CI, Sninsky JJ and Gregersen PK: **A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.** *Am J Hum Genet* 2004, **75**:330–337.
 18. Kurreeman FA, Padyukov L, Marques RB, Schrod SJ, Seddighzadeh M, Stoeken-Rijsbergen G, Helm-van Mil van der AH, Allaart CF, Verduyn W, Houwing-Duistermaat J, Alfredsson L, Begovich AB, Klareskog L, Huizinga TW and Toes RE: **A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis.** *PLoS Med* 2007, **4**:e278.
 19. **University of California at Santa Clara Genome Browser.** <http://genome.ucsc.edu/cgi-bin/hgGateway>.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

